Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;15(7):615-627.
doi: 10.4155/fmc-2022-0287. Epub 2023 May 4.

Investigation of carbonic anhydrase inhibitory potency of (Z/E)-alkyl N'-benzyl- N-(arylsulfonyl)-carbamimidothioates

Morteza Abdoli  1 , Viviana De Luca  2 , Clemente Capasso  2 , Claudiu T Supuran  3 , Raivis Žalubovskis  1   4
Affiliations

Investigation of carbonic anhydrase inhibitory potency of (Z/E)-alkyl N'-benzyl- N-(arylsulfonyl)-carbamimidothioates

Morteza Abdoli et al. Future Med Chem. 2023 Apr.

Abstract

Aim: Among 15 human (h) carbonic anhydrase (CA; EC 4.2.1.1) isoforms, two (hCA IX and XII) play important roles in the growth and survival of tumor cells, making them therapeutic targets for cancer treatment. This study aimed to develop novel sulfonamide-based compounds as selective hCA IX and XII inhibitors. Materials & methods: A library of novel N-sulfonyl carbamimidothioates was obtained for CA inhibitory activity studies against four hCA isoforms. Results: None of the developed compounds displayed inhibitory potential against off-target isoforms hCA I and II. However, they effectively inhibited tumor-associated hCA IX and XII. Conclusion: The present study suggests potent lead compounds as selective hCA IX and XII inhibitors with anticancer activity.

Keywords: (Z/E)-alkyl N'-benzyl-N-(arylsulfonyl)-carbamimidothioates; antitumor; carbonic anhydrase; inhibitors; sulfonamides.

PubMed Disclaimer

Publication types

LinkOut - more resources